ArticlePhytomedicine : international journal of phytotherapy and phytopharmacology2021
Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
Article in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 107 citations in OpenAlex.
- Development and Application of a Dual-Fluorescent Reporter Assay for Feline Infectious Peritonitis Virus RNA-Dependent RNA Polymerase Inhibitor Screening.International journal of molecular sciences · 2026Article
- Targeting β2-Adrenergic Receptor Stability With Lycorine Reveals a Host-Directed Pathway for Antiviral Defense Against Poxviruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cross-Family Mechanistic Analysis of Plant Alkaloids Against Neglected Arboviruses and Related RNA Viruses.Molecules (Basel, Switzerland) · 2026Review
- Discovery and mutasynthetic optimization of ansatrienin B: A new broad-spectrum inhibitor against RNA viruses.Acta pharmaceutica Sinica. B · 2026Article
- Lycorine Derivative Inhibits SARS-CoV-2 Replication by Reducing -1 Programmed Ribosomal Frameshifting via Targeting ZAP.MedComm · 2026Article
- Natural Alkaloids as Antiviral Agents Against RNA Viruses: A Comprehensive and Mechanistic Review.Molecules (Basel, Switzerland) · 2026Review
- Amaryllidaceae Alkaloids and Phenolic Acids Identification inMolecules (Basel, Switzerland) · 2026Article
- Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan-Coronavirus Inhibitor.MedComm · 2025Article
- How Can Plant-Derived Natural Products and Plant Biotechnology Help Against Emerging Viruses?International journal of molecular sciences · 2025Review
- Lycorine Inhibits Influenza Virus Replication by Affecting Nascent Nucleoporin Nup93 Synthesis.International journal of molecular sciences · 2025Article
- Glycyl-tRNA Synthetase as a Target for Antiviral Drug Screening Against Influenza Virus.International journal of molecular sciences · 2025Article
- Antiviral alkaloids fromHeliyon · 2025Article
- Amaryllidaceae Alkaloids Screen Unveils Potent Anticoronaviral Compounds and Associated Structural Determinants.ACS pharmacology & translational science · 2024Article
- Lycorine (Lycoris radiata)-a unique natural medicine on breast cancer.Journal of cellular and molecular medicine · 2024Article
- How does water stress affect the bioaccumulation of galanthamine and lycorine, growth performance, phenolic content and defense enzyme activities in summer snowflake (Physiology and molecular biology of plants : an international journal of functional plant biology · 2024Article
- Article
- Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets.Pharmaceutical biology · 2023Review
- Benzoindolizidine Alkaloids Tylophorine and Lycorine and Their Analogues with Antiviral, Anti-Inflammatory, and Anticancer Properties: Promises and Challenges.Biomedicines · 2023Review
- Article
- Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids fromMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHighly effective novel treatments need to be developed to suppress emerging coronavirus (CoV) infections such as COVID-19. The RNA dependent RNA polymerase (RdRp) among the viral proteins is known as an effective antiviral target. Lycorine is a phenanthridine Amaryllidaceae alkaloid isolated from the bulbs of Lycoris radiata (L'Hér.) Herb. and has various pharmacological bioactivities including antiviral function. PURPOSE: We investigated the direct-inhibiting action of lycorine on CoV's RdRp, as potential treatment for emerging CoV infections.
methodsWe examined the inhibitory effect of lycorine on MERS-CoV, SARS-CoV, and SARS-CoV-2 infections, and then quantitatively measured the inhibitory effect of lycorine on MERS-CoV RdRp activity using a cell-based reporter assay. Finally, we performed the docking simulation with lycorine and SARS-CoV-2 RdRp.
resultsLycorine efficiently inhibited these CoVs with IC
conclusionsLycorine is a potent non-nucleoside direct-acting antiviral against emerging coronavirus infections and acts by inhibiting viral RdRp activity; therefore, lycorine may be a candidate against the current COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.